Renalytix shifts year-end to December 31, extends reporting cycle

Renalytix plc has adjusted its financial year-end from June 30 to December 31, extending its reporting cycle to 18 months and aligning it with its operational strategy. The change means the company’s audited results for the period ending June 30, 2025, will now cover the full year through December 31, 2026. Following this, interim results for the six-month period ending December 31, 2025, are scheduled for publication in March 2026. Unaudited interim results for the 12-month period ending June 30, 2026, are expected in late October 2026, with audited accounts for the 18-month period due no later than June 30, 2027, in compliance with AIM Rule 19. Moving forward, the company will adopt a standard 12-month financial year, with interim results covering the six months to June 30 each year. The shift reflects Renalytix’s goal of synchronizing its reporting cycle with its strategic planning, particularly as it advances its partnership with Quest Diagnostics. Through this collaboration, the kidney-focused diagnostics platform `kidneyintelX.dkd` is set to be available for physician ordering in the first quarter of 2027. Renalytix, a precision medicine diagnostics company specializing in kidney disease, continues to position itself as a key player in diagnostic innovation.